
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Location: United States, Massachusetts, Boston
Member count: 51-200
Total raised: $73M
Founded date: 2001
Investors 3
Date | Name | Website |
07.08.2021 | New Enterp... | nea.com |
- | Hercules C... | htgc.com |
- | Prospect V... | prospectve... |
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
12.03.2021 | - | $20M | - | - |
04.05.2007 | - | $53M | - | venturebea... |
Mentions in press and media 7
Date | Title | Description | Category | Author | Source |
18.10.2022 | South Kore... | SEOUL: South Korea's LG Chem s... | - | - | channelnew... |
04.11.2019 | AVEO Oncol... | The FDA said that if the compa... | - | - | medcitynew... |
31.01.2019 | FDA stiff-... | → Aveo Oncology was hit wit... | - | Endpoints ... | endpts.com... |
23.06.2017 | Merck KGa... | → Cladribine is back. Once gi... | - | Emma Yasin... | endpts.com... |
04.05.2007 | Cancer-dru... | Aveo Pharmaceuticals, a Cambri... | - | - | venturebea... |
- | AVEO Oncol... | The Food and Drug Administrati... | - | - | medcitynew... |
- | AVEO Oncol... | BOSTON--(BUSINESS WIRE)--Mar 1... | - | - | oaoa.com/n... |